Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taiwan, Japan Eye Drug Regulation Streamlining To Curb Costs

This article was originally published in PharmAsia News

Executive Summary

Regulators from Japan and Taiwan met in late December to review prospects for convergence and pointed to manufacturing and new drug approvals as areas that were ripe for harmonization agreements.

You may also be interested in...

Taiwan Looks To Generic Savings In HIV Drug Reimbursement To Build On Multinational Price Cuts

Following an agreement by six multinational firms – including GlaxoSmithKline and AbbVie – to cut prices for antiretrovirals, Taiwan’s Centers for Disease Control is looking to import generic drugs for its free HIV drug reimbursement program, which has met with success only to see costs explode.

Taiwan Seeks Help From Biotechs To Develop H7N9 Vaccine

Taiwan plans to move as quickly to solicit help from private biotech companies to produce a vaccine for the deadly H7N9 avian flu, with other Asian government watching closely to see if cases appear outside of mainland China.

Reading The Cultural Nuances Key In Managing Clinical Trials In Asia

Companies need to acknowledge that culture plays a major role in pushing clinical trials in Asia, which makes first steps crucial in working with regulators, hospitals and patients.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts